Prashant Kumar Following the issuance of a Form FDA 483, the window for regulatory advocacy is brief and high-stakes, necessitating a response that serves as a cornerstone for future enforcement decisions. While the industry has long relied on historical precedent and unofficial best practices, the March 2026 draft guidance finally formalizes the Agency’s expectations for post-inspection communication. … Read more
In pharmaceutical development, regulatory exclusivity can create a powerful competitive moat—often determining whether an innovative lifecycle strategy translates into meaningful market differentiation. The U.S. Food and Drug Administration (FDA) has released a draft guidance providing long-awaited clarity on the statutory and regulatory framework governing three-year exclusivity under the Hatch-Waxman Amendments. For regulatory affairs leaders, portfolio … Read more
Real-world data (RWD) has transitioned from an exploratory research asset to a strategic regulatory tool shaping post-market drug safety evaluations. As healthcare systems generate increasingly complex datasets, from electronic health records to insurance claims and disease registries, regulators are demanding more rigorous frameworks for translating these data into regulatory-grade evidence. The FDA’s adoption of the … Read more
For nearly a decade, basic scientists have wrestled with a classification that felt like a square peg in a round hole: the BESH designation. By labeling fundamental human behavior studies as “clinical trials,” the NIH sparked years of debate over administrative burden versus scientific transparency. Now, a massive policy shift is officially on the horizon, … Read more
The standard regulatory threshold of “substantial evidence of effectiveness” has historically relied on large-scale randomized controlled trials (RCTs) to mitigate statistical noise. For ultra-rare genetic conditions, however, the laws of small numbers make traditional RCTs practically and ethically unfeasible. The FDA’s latest guidance introduces a “Plausible Mechanism Framework” to bridge this gap, allowing deep molecular … Read more
Keeping pace with the rapid evolution of medical technology requires a regulatory framework that is both rigorous and agile. The FDA’s latest announcement regarding the Food and Drug Administration Modernization Act of 1997 represents a vital step in aligning regulatory expectations with modern engineering. By updating its list of recognized consensus standards, the agency is … Read more
The FDA’s transition to a single-trial default for drug and biologic approvals marks a pivotal evolution in regulatory philosophy, moving away from the 1962 Kefauver-Harris dual-study precedent. For industry leadership, this shift offers a significant opportunity to accelerate speed-to-market, provided that clinical programs are built on a foundation of absolute statistical and biological rigor. However, … Read more
Artificial intelligence (AI) and advanced modeling are reshaping how drugs and biologics are developed, reviewed, and regulated worldwide. In late 2024 and early 2025, the FDA released draft guidance on AI use in regulatory submissions, while the International Council for Harmonization (ICH) finalized its M15 guideline on model-informed drug development (MIDD). Together, these documents signal … Read more
What if regulatory decisions reflected not just clinical endpoints, but what patients truly value? What if benefit–risk assessments explicitly accounted for patients’ willingness to accept uncertainty, risk, or trade-offs? The FDA’s adoption of ICH E22 signals its perspective on using patient preferences for regulatory decisions by formalizing how structured patient preference data can be designed, … Read more
For decades, pharmaceutical manufacturing steadily migrated overseas, leaving the U.S. dependent on fragile global supply chains. With the launch of the FDA PreCheck pilot program, the agency is offering manufacturers something long requested: regulatory predictability before product submission. FDA PreCheck is designed to strengthen the domestic pharmaceutical supply chain by facilitating the construction of U.S.-based … Read more
